A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine With Two Different Serotype 2 Potencies in an Adult Population in Singapore

Trial Profile

A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine With Two Different Serotype 2 Potencies in an Adult Population in Singapore

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs TAK 003 (Primary)
  • Indications Dengue
  • Focus Pharmacodynamics
  • Sponsors Takeda
  • Most Recent Events

    • 31 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 07 Jul 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017.
    • 07 Jul 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top